Alaunos Therapeutics (TCRT) Registration Filing summary

Company overview and business model

• Focused on developing a preclinical small molecule oral obesity program with a differentiated, non-hormonal mechanism of action targeting obesity and related metabolic disorders.

• Previously operated as a clinical-stage oncology cell therapy company but reprioritized in August 2023, winding down TCR-T programs due to high costs and challenging financing.

• Exploring strategic alternatives including acquisitions, mergers, asset sales, partnerships, or capital raises.

Financial performance and metrics

• No product revenue generated to date; significant net losses incurred each year since inception.

• Net loss of $2.1 million for the six months ended June 30, 2025; accumulated deficit of $922.6 million since 2003.

• R&D expenses for cancer programs declined from $11.7 million (six months ended June 30, 2023) to $0.3 million (same period in 2025) due to strategic shift.

• Stockholders' equity was $3.66 million as of June 30, 2025, after previously falling below Nasdaq's $2.5 million minimum.

Use of proceeds and capital allocation

• Net proceeds from the primary offering will be used for general corporate purposes, including acquisitions, debt repayment, investments, working capital, and capital expenditures.

• Management retains broad discretion over allocation; proceeds from resale by selling stockholders will not go to the company.